학술논문
Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, PD-L1+≥50% of tumor cells in France: A modeling study
Document Type
Article
Author
Source
In Lung Cancer October 2023 184
Subject
Language
ISSN
0169-5002